Special Considerations in the Management of HIV-Infected Patients From Minority Communities

  • Authors: Bisola Ojikutu, MD, MPH; Valerie E. Stone, MD, MPH (More Info)
  • Section Editor: Judith S. Currier, MD, MSc
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/9/18 (What's New)

Summary

  • A subanalysis of ACTG 5095 found that a genetic polymorphism in the CYP2B6 gene associated with higher plasma efavirenz concentrations and increased central nervous system toxicity occurred more frequently in blacks than in whites[Haas 2004]
  • Early adverse events may have contributed to reduced adherence in black patients

Action required

Keywords: Initial Antiretroviral Therapy, Minority-Ethnic Communities, Pharmacokinetics, Special Populations

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.